Low-dose paclitaxel elution by novel bioerodible sol-gel coating on stents inhibits neointima with low toxicity in porcine coronary arteries

Endothelium-Dependent Vasomotor Dysfunction in Pig Coronary Arteries With Paclitaxel-Eluting Stents Is Associated With Inflammation and Oxidative Stress

“…Sections from the overlapped-stent region were cut using a heavy-duty microtome, collected on glass slides, and stained with hematoxylin-eosin and Movat-Pentachrome. According to previously published methods (16), intramural thrombus (a mixture of fibrin, para-strut amorphous mate- rial and red blood cell debris) and inflammation were scored in all sections: 0 ϭ not present; 1 ϭ mild (scattered); 2 ϭ moderate (encompassing Ͻ50% of a strut in at least 25% to 50% of the circumference length); and 3 ϭ severe (surrounding a strut in at least 50% of the circumference length). Similarly, necrosis of the tunica media was also scored: 0 ϭ none; 1 ϭ mild [focal transmural or nontransmural region of medial smooth muscle cell (SMC) necrosis involving any portion of the artery]; 2 ϭ moderate (transmural medial SMC necrosis involving Ͼ25% of the circumference of the artery); and 3 ϭ severe (transmural medial SMC necrosis with involvement of Ͼ50% of the circumference of the artery).…”

“…Aside from the metal struts, PES contains 2 important components: nonbiodegradable synthetic polymer and paclitaxel. Due to the polymer lipophilicity, only 10% of the initial drug dose can be released from the current slow-release formulation of TAXUS, leaving the residual 90% of the drug in a tissuebound form (16,21). Multiple factors, including direct toxic effect from the entrapped drug or an acute or delayed hypersensitivity reaction from the polymer and/or drug, may cause DES-triggered vasomotor dysfunction.…”

Paclitaxel-polyurethane film for anti-cancer drug delivery: Film characterization and preliminary in vivo study

“…E-mails: spark@eulji.ac.kr or ldh@inha.ac.kr paclitaxel or an immunosuppressive drug sirolimus for the control of neointimal hyperplasia after stent placement has been a great success for treatment of coronary artery obstruction. [10][11][12][13] This local stent-based drug delivery could also be applied to the gastrointestinal obstruction for the purpose of controlling the malignant tumor around the non-vascular stents. For successful local delivery of paclitaxel from the stent to tumor, we developed a paclitaxel-incorporated polyurethane (PTX-PU) film, and investigated its morphology by scanning electron microscopy (SEM), in vitro drug release behavior, and in vivo anti-cancer efficacy for suppression of solid tumor for potential application to stent placement in obstructed gastrointestinal tract due to malignant tumor.…”

Vasomotor Function After Paclitaxel-Coated Balloon Post-Dilation in Porcine Coronary Stent Model

“…Per standard protocol of our group (25), after full heparinization (200 U/kg), cardiac catheterization and stents were implanted. Quantitative coronary angiography guidance was used to obtain a stent-to-artery diameter ratio of 1.1:1.…”